Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | ACACB | O00763 | 7/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12932743 | 0.79 | CACNA1I (0.57) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL3090845 | 0.78 | CACNA1I (0.50) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL1065226 | 0.76 | CACNA1I (0.65) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL13181919 | 0.72 | CACNA1I (0.65) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL3093274 | 0.70 | CACNA1I (0.47) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL15880148 | 0.69 | HRH3 (0.48) | PPARGPPARDPPARAJAK2JAK3 | |
| SCHEMBL1063999 | 0.69 | CACNA1I (0.67) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL1061452 | 0.69 | CACNA1I (0.73) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL11977139 | 0.69 | GFER (0.47) | PPARGPPARDPPARAJAK2JAK3 | |
| SCHEMBL3096617 | 0.69 | CACNA1I (0.48) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249176-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249176-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1G 1/4885CACNA1H 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.